May Kazem MD MHA FRCPC
@drmkazem.bsky.social
Rheumatologist | Interested in Scleroderma and Bone health | @UBC
🤓
🤓
Reposted by May Kazem MD MHA FRCPC
🆕 Clinical Year in Review at #ACR25
By Dr. Bryant England @unmc.bsky.social
🔶 Review the most impactful studies in #Rheumatology from the past year!
❓ Any studies you would add to the list?
#RheumSky #MedSky #YearInReview
By Dr. Bryant England @unmc.bsky.social
🔶 Review the most impactful studies in #Rheumatology from the past year!
❓ Any studies you would add to the list?
#RheumSky #MedSky #YearInReview
October 29, 2025 at 6:00 PM
🆕 Clinical Year in Review at #ACR25
By Dr. Bryant England @unmc.bsky.social
🔶 Review the most impactful studies in #Rheumatology from the past year!
❓ Any studies you would add to the list?
#RheumSky #MedSky #YearInReview
By Dr. Bryant England @unmc.bsky.social
🔶 Review the most impactful studies in #Rheumatology from the past year!
❓ Any studies you would add to the list?
#RheumSky #MedSky #YearInReview
Reposted by May Kazem MD MHA FRCPC
Acute and chronic viral infections, including Herpes Zoster (Shingles), Hepatitis C, HIV, CMV, influenza, and SARS-CoV-2, are linked with a substantial increased risk of cardiovascular events, from a systematic review. Figure for SARS-CoV-2 below
newsroom.heart.org/news/some-ac...
newsroom.heart.org/news/some-ac...
October 29, 2025 at 1:26 PM
Acute and chronic viral infections, including Herpes Zoster (Shingles), Hepatitis C, HIV, CMV, influenza, and SARS-CoV-2, are linked with a substantial increased risk of cardiovascular events, from a systematic review. Figure for SARS-CoV-2 below
newsroom.heart.org/news/some-ac...
newsroom.heart.org/news/some-ac...
Reposted by May Kazem MD MHA FRCPC
🆕 Secrets & Pearls of #Rheumatology at #ACR25 | Part 1 by Dr. Janet Pope
🖐️ Cutaneous Pathology SLE/DM
🧴 Tips for SLE
💪 Cancer Screening in Myositis
🩸 Laboratory Testing
🥶 Raynaud's / Scleroderma
👀 Sjogrens Disease
#RheumSky #MedSky #Lupus #Myositis #Scleroderma #Sjogrens
🖐️ Cutaneous Pathology SLE/DM
🧴 Tips for SLE
💪 Cancer Screening in Myositis
🩸 Laboratory Testing
🥶 Raynaud's / Scleroderma
👀 Sjogrens Disease
#RheumSky #MedSky #Lupus #Myositis #Scleroderma #Sjogrens
October 28, 2025 at 11:02 PM
🆕 Secrets & Pearls of #Rheumatology at #ACR25 | Part 1 by Dr. Janet Pope
🖐️ Cutaneous Pathology SLE/DM
🧴 Tips for SLE
💪 Cancer Screening in Myositis
🩸 Laboratory Testing
🥶 Raynaud's / Scleroderma
👀 Sjogrens Disease
#RheumSky #MedSky #Lupus #Myositis #Scleroderma #Sjogrens
🖐️ Cutaneous Pathology SLE/DM
🧴 Tips for SLE
💪 Cancer Screening in Myositis
🩸 Laboratory Testing
🥶 Raynaud's / Scleroderma
👀 Sjogrens Disease
#RheumSky #MedSky #Lupus #Myositis #Scleroderma #Sjogrens
Reposted by May Kazem MD MHA FRCPC
October 29, 2025 at 12:01 AM
Reposted by May Kazem MD MHA FRCPC
October 27, 2025 at 8:03 PM
Reposted by May Kazem MD MHA FRCPC
October 28, 2025 at 12:02 AM
Reposted by May Kazem MD MHA FRCPC
October 27, 2025 at 4:06 PM
Reposted by May Kazem MD MHA FRCPC
#ACR25: @jyazdanymd.bsky.social chief of rheumatology at San Francisco General Hospital @ucsanfrancisco.bsky.social at the 2025 ACR Convergence, as part of session, “The Great Debate in AI: Unlocking Potential or Unleashing Chaos?”
Image & quote taken by Larry Luxner
#RareDisease #RheumSky #MedSky
Image & quote taken by Larry Luxner
#RareDisease #RheumSky #MedSky
October 27, 2025 at 4:40 PM
#ACR25: @jyazdanymd.bsky.social chief of rheumatology at San Francisco General Hospital @ucsanfrancisco.bsky.social at the 2025 ACR Convergence, as part of session, “The Great Debate in AI: Unlocking Potential or Unleashing Chaos?”
Image & quote taken by Larry Luxner
#RareDisease #RheumSky #MedSky
Image & quote taken by Larry Luxner
#RareDisease #RheumSky #MedSky
Reposted by May Kazem MD MHA FRCPC
#ACR25: Jeff Curtis, MD, professor of medicine at UAB, speaking at the 2025 ACR Convergence in Chicago as part of a session titled “The Great Debate in AI: Unlocking Potential or Unleashing Chaos?”
Image & quote taken by, Larry Luxner
#RareDisease #Rheumatology #AI #MedTech #RheumSky
Image & quote taken by, Larry Luxner
#RareDisease #Rheumatology #AI #MedTech #RheumSky
October 27, 2025 at 4:20 PM
#ACR25: Jeff Curtis, MD, professor of medicine at UAB, speaking at the 2025 ACR Convergence in Chicago as part of a session titled “The Great Debate in AI: Unlocking Potential or Unleashing Chaos?”
Image & quote taken by, Larry Luxner
#RareDisease #Rheumatology #AI #MedTech #RheumSky
Image & quote taken by, Larry Luxner
#RareDisease #Rheumatology #AI #MedTech #RheumSky
Reposted by May Kazem MD MHA FRCPC
FDA Approves Obinutuzumab for Active Lupus Nephritis
The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.
buff.ly/my15Pnn
The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.
buff.ly/my15Pnn
October 21, 2025 at 11:01 PM
FDA Approves Obinutuzumab for Active Lupus Nephritis
The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.
buff.ly/my15Pnn
The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.
buff.ly/my15Pnn
Reposted by May Kazem MD MHA FRCPC
What do rheumatologists & hematologists need to know about Castleman disease? In our NEWEST episode, we unpack diagnosis, treatment, & the evolving understanding of this complex condition
LISTEN NOW🎙️→ acr.tw/48lersf
LISTEN NOW🎙️→ acr.tw/48lersf
September 20, 2025 at 12:18 AM
What do rheumatologists & hematologists need to know about Castleman disease? In our NEWEST episode, we unpack diagnosis, treatment, & the evolving understanding of this complex condition
LISTEN NOW🎙️→ acr.tw/48lersf
LISTEN NOW🎙️→ acr.tw/48lersf
Reposted by May Kazem MD MHA FRCPC
An editorial on the paper from @dfeterman.bsky.social & @alisonbays.bsky.social examining the impact of insurance prior authorizations on individuals with giant cell arteritis (risk of blindness if not treated) in WA state
Thank you to @jrheumatol.bsky.social for publishing & highlighting
Thank you to @jrheumatol.bsky.social for publishing & highlighting
Editorial
Does Prior Authorization for Tocilizumab Lead to Unacceptable Treatment Delays in Giant Cell Arteritis?
📖 doi.org/10.3899/jrhe...
@westernu.ca
#giantcellarteritis #vasculitis
Does Prior Authorization for Tocilizumab Lead to Unacceptable Treatment Delays in Giant Cell Arteritis?
📖 doi.org/10.3899/jrhe...
@westernu.ca
#giantcellarteritis #vasculitis
July 4, 2025 at 1:49 PM
An editorial on the paper from @dfeterman.bsky.social & @alisonbays.bsky.social examining the impact of insurance prior authorizations on individuals with giant cell arteritis (risk of blindness if not treated) in WA state
Thank you to @jrheumatol.bsky.social for publishing & highlighting
Thank you to @jrheumatol.bsky.social for publishing & highlighting
Local immune effector cell-associated toxicity syndrome (LICATS) in #CART-cell treated patients with autoimmune disease: an observational study - The Lancet Rheumatology www.thelancet.com/journals/lan...
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study
LICATS is a new form of toxicity in patients with autoimmune disease receiving CD19-targeting
CAR T-cell therapy, most likely based on the cleansing of immune cells from the affected
organs. It is sel...
www.thelancet.com
May 20, 2025 at 1:31 PM
Local immune effector cell-associated toxicity syndrome (LICATS) in #CART-cell treated patients with autoimmune disease: an observational study - The Lancet Rheumatology www.thelancet.com/journals/lan...
Reposted by May Kazem MD MHA FRCPC
Trial of metformin for knee #osteoarthritis showed improvement in knee pain vs. placebo. What’s the mechanism? Curious to see what the weight loss differences were been groups.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Metformin for Knee Osteoarthritis in Patients With Overweight or Obesity
This randomized clinical trial assesses the effect of metformin on knee pain among patients with symptomatic knee osteoarthritis and overweight or obesity.
jamanetwork.com
May 20, 2025 at 11:59 AM
Trial of metformin for knee #osteoarthritis showed improvement in knee pain vs. placebo. What’s the mechanism? Curious to see what the weight loss differences were been groups.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted by May Kazem MD MHA FRCPC
Tolebrutinib is a BTK inhibitor that is being studied for the treatment of relapsing multiple sclerosis. Research findings from the GEMINI 1 and GEMINI 2 trials comparing tolebrutinib with teriflunomide are summarized in a new Quick Take video. nej.md/3S1hY5N
#MedSky #NeuroSky
#MedSky #NeuroSky
Tolebrutinib versus Teriflunomide in Multiple Sclerosis | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Tolebrutinib versus Teriflunomide in Multiple Sclerosis
nej.md
May 20, 2025 at 1:03 PM
Tolebrutinib is a BTK inhibitor that is being studied for the treatment of relapsing multiple sclerosis. Research findings from the GEMINI 1 and GEMINI 2 trials comparing tolebrutinib with teriflunomide are summarized in a new Quick Take video. nej.md/3S1hY5N
#MedSky #NeuroSky
#MedSky #NeuroSky
Reposted by May Kazem MD MHA FRCPC
single-centre study of 469 consecutive RA pts - 15 had VTE (3%). Strongest risk factor of VTE was the history of previous VTE (OR 44.7), recent hospitalisation (OR 6.82), diabetes (OR 11.23), and JAKi (OR 5.54) (Other studies show inflammation incr VTE risk) pubmed.ncbi.nlm.nih.gov/40314997/
Risk factors associated with venous thromboembolism in rheumatoid arthritis in clinical practice - PubMed
In this study of RA patients, history of VTE and recent hospitalisation were identified as strong risk factors of VTE. Moreover, it emphasises the importance of evaluating cardiovascular risk…
pubmed.ncbi.nlm.nih.gov
May 6, 2025 at 6:02 PM
single-centre study of 469 consecutive RA pts - 15 had VTE (3%). Strongest risk factor of VTE was the history of previous VTE (OR 44.7), recent hospitalisation (OR 6.82), diabetes (OR 11.23), and JAKi (OR 5.54) (Other studies show inflammation incr VTE risk) pubmed.ncbi.nlm.nih.gov/40314997/
Inclusion of results from new large RCTs provides further robust evidence that the addition of low-dose colchicine to standard-of-care therapy decreases the incidence of MACE, MI, ischaemic stroke, & recurrent coronary revascularization in vascular disease patients
academic.oup.com/eurheartj/ad...
academic.oup.com/eurheartj/ad...
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis
AbstractBackground and Aims. Colchicine has emerged as a safe and inexpensive anti-inflammatory medication to target the residual risk of cardiovascular ev
academic.oup.com
May 12, 2025 at 12:14 PM
Inclusion of results from new large RCTs provides further robust evidence that the addition of low-dose colchicine to standard-of-care therapy decreases the incidence of MACE, MI, ischaemic stroke, & recurrent coronary revascularization in vascular disease patients
academic.oup.com/eurheartj/ad...
academic.oup.com/eurheartj/ad...
Adding Acrometastases to synovitis differential 🤯
A 74 y/o woman was referred for osteoarthritis with pain over the base of her right thumb. Hand x-ray (A) showed advanced OA of the first CMC joint. She returned 6 months later with 2-week history of pain, swelling, and pitting edema over the dorsum of her right hand and wrist (B)
#Medsky
#Medsky
May 12, 2025 at 12:00 PM
Adding Acrometastases to synovitis differential 🤯
Reposted by May Kazem MD MHA FRCPC
ICYMI: New content online:
Arterial and venous thrombosis in systemic and monogenic vasculitis
Nature Reviews Rheumatology, Published online: 06 May 2025; doi:10.1038/s41584-025-01252-7Systemic vasculitis, including monogenic forms, is associated with an increased risk of arterial and venous thromboembolic events (AVTEs). This Review highlights the latest advances in the understanding of the pathogenesis, clinical features and management of AVTEs in systemic and monogenic vasculitis.
bit.ly
May 11, 2025 at 5:33 PM
ICYMI: New content online:
Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study - eClinicalMedicine www.thelancet.com/journals/ecl...
Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study
Our finding suggest that first-generation GLP1-RA treatment does not increase ORC
risk in patients receiving GLP1-RA treatment for diabetes and weight loss. Moreover,
this may point at additional path...
www.thelancet.com
May 12, 2025 at 11:42 AM
Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study - eClinicalMedicine www.thelancet.com/journals/ecl...